Schroders Capital Global leaps as investee sold for USD400 million

(Alliance News) - Schroders Capital Global Innovation Trust PLC shares jumped on Monday as it ...

Alliance News 17 March, 2025 | 2:13PM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Schroders Capital Global Innovation Trust PLC shares jumped on Monday as it said its investee Araris Biotech AG is set to be bought for USD400 million.

The London-based investment trust said Araris has entered an agreement to be bought by Taiho Pharmaceutical Co Ltd for USD400 million upfront, with the potential for further milestone payments of up to USD740 million.

Shares in Schroders Capital Global Innovation Trust were up 36% to 11.84 pence in London on Monday afternoon.

Araris is a Zurich-based biotechnology company developing next-generation antibody drug conjugates.

The investment trust said the deal values its holding at GBP19.5 million. This is a positive valuation revision of GBP16.7 million compared to its last carrying value of GBP2.8 million as of the end of September last year.

Schroders Capital Global said the impact of the deal on its net asset value will be evaluated at the end of March.

The upfront proceeds from the sale will increase the previously disclosed initial return of capital to GBP28.7 million from GBP10.0 million.

The initial return of capital will take place shortly after the receipt of initial proceeds from the transaction.

The trust said the upfront proceeds will generate a USD24.3 million distribution at closing and potential further distributions of up to USD43.6 million.

Schroders Capital invested in Araris as part of its seed round in 2019, before a further GBP2.6 million investment in October 2022.

Portfolio Managers Tim Creed and Harry Raikes said: "We chose to invest in Araris Biotech based on its compelling platform, with potential best-in-class antibody drug conjugates with superior design, high linker solubility and simple manufacturing that address the shortcomings of current generation ADCs.

"Overall, the company fulfilled our four key investment criteria: a strong management team, a significant market opportunity, high quality science and reputable co-investors. We are delighted by the news of this sale which reflects the unique nature of the Araris platform."

By Michael Hennessey, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Schroders Capital Global Innov Trust Ord 11.45 GBX -4.18

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures